Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CCR9 | P51686 | 2/20 | 0.41 |
| ▸ | RHEB | Q15382 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079495 | 0.80 | CCR2 (0.47) | CCR2CCR9RHEBMAPTTP53 | |
| SCHEMBL6303493 | 0.77 | CCR2 (0.62) | CCR2CCR9RHEBMAPT | |
| SCHEMBL701444 | 0.76 | GPR35 (0.46) | CCR2CCR9RHEBPOLBMAPT | |
| SCHEMBL4209306 | 0.75 | CCR9 (0.56) | CCR2CCR9RHEB | |
| SCHEMBL6300706 | 0.74 | CCR9 (0.53) | CCR2CCR9RHEB | |
| SCHEMBL3964056 | 0.72 | F10 (0.47) | — | |
| SCHEMBL6300781 | 0.71 | CCR2 (0.53) | CCR2CCR9RHEB | |
| SCHEMBL6221773 | 0.70 | HSD17B10 (0.54) | RHEB | |
| SCHEMBL6308101 | 0.66 | CCR2 (1.00) | CCR2ABCB11 | |
| SCHEMBL3963296 | 0.65 | CCR2 (0.72) | CCR2RHEBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953809-B2 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | CCR2 4/4885ABCB11 506/4885CCR9 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.